Published in J Neurosci on January 26, 2005
The melanin-concentrating hormone system modulates cocaine reward. Proc Natl Acad Sci U S A (2009) 1.30
Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors. J Biol Chem (2010) 1.23
Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus. J Neurosci (2008) 1.14
Regulation of nucleus accumbens activity by the hypothalamic neuropeptide melanin-concentrating hormone. J Neurosci (2010) 1.13
Behavioral genetic contributions to the study of addiction-related amphetamine effects. Neurosci Biobehav Rev (2007) 1.08
Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol (2006) 1.07
Hypothalamic melanin concentrating hormone neurons communicate the nutrient value of sugar. Elife (2013) 1.01
Ablation of neurons expressing melanin-concentrating hormone (MCH) in adult mice improves glucose tolerance independent of MCH signaling. J Neurosci (2013) 0.97
A comparative analysis shows morphofunctional differences between the rat and mouse melanin-concentrating hormone systems. PLoS One (2010) 0.93
Animals models of MCH function and what they can tell us about its role in energy balance. Peptides (2009) 0.93
Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology (Berl) (2010) 0.92
Neurochemical characterization of neurons expressing melanin-concentrating hormone receptor 1 in the mouse hypothalamus. J Comp Neurol (2013) 0.91
Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. J Neurosci (2009) 0.87
To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance. Front Syst Neurosci (2015) 0.85
Repeated amphetamine administration induces Fos in prefrontal cortical neurons that project to the lateral hypothalamus but not the nucleus accumbens or basolateral amygdala. Psychopharmacology (Berl) (2007) 0.85
Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice. Br J Pharmacol (2007) 0.85
The melanin-concentrating hormone (MCH) system modulates behaviors associated with psychiatric disorders. PLoS One (2011) 0.85
Chronic loss of melanin-concentrating hormone affects motivational aspects of feeding in the rat. PLoS One (2011) 0.85
A Path to Sleep Is through the Eye(1,2,3). eNeuro (2015) 0.83
A role for Melanin-Concentrating Hormone in learning and memory. Peptides (2009) 0.83
Modulation of Food Reward by Endocrine and Environmental Factors: Update and Perspective. Psychosom Med (2015) 0.80
Electrophysiological effects of MCH on neurons in the hypothalamus. Peptides (2009) 0.80
Expression of melanin-concentrating hormone receptor 2 protects against diet-induced obesity in male mice. Endocrinology (2013) 0.80
Meta-analysis of melanin-concentrating hormone signaling-deficient mice on behavioral and metabolic phenotypes. PLoS One (2014) 0.79
Differential role of D1 and D2 receptors in the perifornical lateral hypothalamus in controlling ethanol drinking and food intake: possible interaction with local orexin neurons. Alcohol Clin Exp Res (2013) 0.79
The regulation of alcohol intake by melanin-concentrating hormone in rats. Pharmacol Biochem Behav (2006) 0.77
The melanin-concentrating hormone-1 receptor modulates alcohol-induced reward and DARPP-32 phosphorylation. Psychopharmacology (Berl) (2016) 0.75
The Melanin-Concentrating Hormone as an Integrative Peptide Driving Motivated Behaviors. Front Syst Neurosci (2017) 0.75
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell (2002) 5.47
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 3.79
Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (2006) 3.55
A method for genetic modification of human embryonic stem cells using electroporation. Nat Protoc (2007) 2.76
An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab (2013) 2.62
mRNA decapping factors and the exonuclease Xrn2 function in widespread premature termination of RNA polymerase II transcription. Mol Cell (2012) 2.57
Diverse psychotomimetics act through a common signaling pathway. Science (2003) 2.52
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry (2007) 2.29
Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell (2009) 2.28
Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J Biol Chem (2007) 1.98
A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat Protoc (2008) 1.95
Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci (2003) 1.78
Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science (2008) 1.77
Influenza surveillance in 15 countries in Africa, 2006-2010. J Infect Dis (2012) 1.76
Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci (2004) 1.67
The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone. Nat Neurosci (2008) 1.57
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A (2007) 1.56
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) (2002) 1.46
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther (2002) 1.43
Senior executive adopt-a-work unit: a model for safety improvement. Jt Comm J Qual Saf (2004) 1.38
Post-transcriptional exon shuffling events in humans can be evolutionarily conserved and abundant. Genome Res (2011) 1.38
Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J Neurosci (2008) 1.35
Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol (2005) 1.35
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol (2003) 1.33
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A (2002) 1.28
How will we know patients are safer? An organization-wide approach to measuring and improving safety. Crit Care Med (2006) 1.28
Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) (2003) 1.28
M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J (2004) 1.25
Delayed 2009 pandemic influenza A virus subtype H1N1 circulation in West Africa, May 2009-April 2010. J Infect Dis (2012) 1.22
Social science. Sacred barriers to conflict resolution. Science (2007) 1.20
Media ion composition controls regulatory and virulence response of Salmonella in spaceflight. PLoS One (2008) 1.19
Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol (2008) 1.19
Brugia malayi: transient transfection by microinjection and particle bombardment. Exp Parasitol (2002) 1.16
The effects of large-scale afforestation and climate change on water allocation in the Macquarie River catchment, NSW, Australia. J Environ Manage (2002) 1.12
Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides (2004) 1.11
Primary mediastinal synovial sarcoma. Ulster Med J (2007) 1.11
The amygdala, panic disorder, and cardiovascular responses. Ann N Y Acad Sci (2003) 1.11
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys (2004) 1.11
The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur J Neurosci (2005) 1.10
The problem of patient heterogeneity and lack of proper training in a study of EEG neurofeedback in children. J Clin Psychiatry (2014) 1.09
Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol (2006) 1.07
Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J Neurosci (2006) 1.07
Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology (2006) 1.06
The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berl) (2005) 1.04
Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol (2003) 1.04
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest (2006) 1.04
Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.03
Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol (2005) 1.02
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology (2002) 1.01
DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc Natl Acad Sci U S A (2002) 1.01
Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry (2005) 1.00
Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci (2007) 1.00
Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci (2003) 0.99
Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav (2002) 0.99
Regulation of cAMP responses by the G12/13 pathway converges on adenylyl cyclase VII. J Biol Chem (2008) 0.98
Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology (2005) 0.98
A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol Sci (2005) 0.97
KDM4B is a master regulator of the estrogen receptor signalling cascade. Nucleic Acids Res (2013) 0.96
Formation of Hirano bodies in Dictyostelium and mammalian cells induced by expression of a modified form of an actin-crosslinking protein. J Cell Sci (2002) 0.96
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res (2009) 0.96
CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology (Berl) (2004) 0.96
Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol (2009) 0.96
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther (2006) 0.94
The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction. J Pharmacol Exp Ther (2003) 0.94
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography. Neuropharmacology (2012) 0.94
Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice. J Immunol (2010) 0.93
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol (2006) 0.93
Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology (Berl) (2010) 0.92
Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology (2007) 0.91
Different effects of subchronic doses of 17-beta estradiol in two ethologically based models of anxiety utilizing female rats. Horm Behav (2004) 0.91
Teaching health workers malaria diagnosis. PLoS Med (2005) 0.91
Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behav Pharmacol (2007) 0.90
Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol (2010) 0.90
Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes. J Biol Chem (2004) 0.89
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol (2009) 0.89
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology (2008) 0.89
CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol (2006) 0.89
Effect of nicotine on body composition in mice. J Endocrinol (2011) 0.88
External validity of the pediatric cardiac quality of life inventory. Qual Life Res (2010) 0.88
A systems genetic analysis of high density lipoprotein metabolism and network preservation across mouse models. Biochim Biophys Acta (2011) 0.88
Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.88
Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine (2006) 0.87
Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J Pharmacol Exp Ther (2009) 0.86
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) (2006) 0.86
Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur J Pharmacol (2006) 0.86
Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine. Int J Neuropsychopharmacol (2008) 0.85
WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res (2003) 0.85
Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist. Eur J Pharmacol (2003) 0.85